AI Article Synopsis
- The study aimed to evaluate levels of free fetal DNA in maternal plasma during pregnancy and its association with conditions like preeclampsia and fetal growth restriction.
- Blood samples from 138 singleton male pregnancies were analyzed, categorizing them into normal pregnancies, preeclampsia, and fetal growth restriction to determine gestational age-related DNA levels.
- Results indicated that free fetal DNA levels rise with gestational age and are notably higher in pregnancies with complications, suggesting its potential as a marker for placental dysfunction, warranting further research.
Article Abstract
Objective: To assess the normal levels of free fetal DNA in maternal plasma through pregnancy compared with those in pregnancies complicated with placental dysfunction manifested by preeclampsia and/or fetal growth restriction.
Study Design: Maternal blood samples from 138 singleton male pregnancies were divided into 3 groups; normal pregnancies (77), preeclampsia (49), and fetal growth restriction (12). Royston and Wright's methods were used to calculate gestational age-related reference limits of free fetal DNA in the 3 groups. The DYS14 gene of the Y chromosome was quantified and compared in maternal plasma by using real-time quantitative polymerase chain reaction.
Results: Free fetal DNA in normal pregnancies increased with gestational age. Results were significantly higher in preeclampsia and fetal growth restriction groups than in normal pregnancy and were higher in severe preeclampsia than in milder disease.
Conclusion: Free fetal DNA is a potential marker for placental dysfunction in pregnancy. Large prospective studies are now needed to investigate its role in the prediction of pregnancy complications and severity and or timing of delivery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajog.2008.07.063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Noncoding variants and sulcal patterns in congenital heart disease: Machine learning to predict functional impact.
iScience
February 2025
Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Neurodevelopmental impairments associated with congenital heart disease (CHD) may arise from perturbations in brain developmental pathways, including the formation of sulcal patterns. While genetic factors contribute to sulcal features, the association of noncoding variants (ncDNVs) with sulcal patterns in people with CHD remains poorly understood. Leveraging deep learning models, we examined the predicted impact of ncDNVs on gene regulatory signals.
View Article and Find Full Text PDFModel construction and clinical therapeutic potential of engineered cardiac organoids for cardiovascular diseases.
Biomater Transl
November 2024
Cardiac Regeneration and Ageing Lab, School of Medicine, Shanghai University, Shanghai, China.
Cardiovascular diseases cause significant morbidity and mortality worldwide. Engineered cardiac organoids are being developed and used to replicate cardiac tissues supporting cardiac morphogenesis and development. These organoids have applications in drug screening, cardiac disease models and regenerative medicine.
View Article and Find Full Text PDFEnhancing Bioactivity of Titanium-Based Materials Through Chitosan Based Coating and Calcitriol Functionalization.
Ann Biomed Eng
January 2025
Department of Biomedical Engineering, Yildiz Technical University, Esenler, 34220, Istanbul, Türkiye.
Titanium (Ti)-based materials are favored for hard tissue applications, yet their bioinertness limits their success. This study hypothesizes that functionalizing Ti materials with chitosan nano/microspheres and calcitriol (VD) will enhance their bioactivity by improving cellular activities and mineralization. To test this, chitosan particles were applied uniformly onto Ti surfaces using electrophoretic deposition (EPD) at 20 V for 3 minutes.
View Article and Find Full Text PDFMaternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review.
Arch Gynecol Obstet
January 2025
Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Purpose: To quantify the separation between maternal blood cell-free (cf)DNA markers in preeclampsia and unaffected pregnancies and compare with existing markers. This approach has not been used in previous studies.
Methods: Comprehensive systematic literature search of PubMed to identify studies measuring total cfDNA, fetal cf(f)DNA or the fetal fraction (FF) in pregnant women.
The association between the amount of fetal fraction in cell-free DNA testing and adverse pregnancy outcomes: A cohort study.
Int J Reprod Biomed
November 2024
Department of Obstetrics and Gynecology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Background: Noninvasive perinatal testing is a new method of screening for aneuploidy called cell-free DNA (cfDNA). Fetal fraction (FF) plays a crucial role in assessing the reliability of aneuploidy detection through noninvasive perinatal testing.
Objective: We aimed to investigate the association between the amount of FF in cfDNA testing and adverse pregnancy outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!